Oliver Schon Email & Phone Number

Cambridge, Gb

Macclesfield, Cheshire, Gb

Macclesfield, Cheshire, Gb

I joined a fledging SME tasked to define and develop the USPs for this Bispecific ADC(antibody drug conjugate) venture with ambitious timelines to clinical development. Asa public company (AIM: BVX.L), I update the Board of Directors (BoD) on progressand provide strategy & mitigation plans in support of company objectives. The roleremit is broad spanning team & technical capability set-up, developability assessmentof leads against Target&Product Profile, CDMO/CRO engagement & management,biological target & lead compound discovery, new technology development as well asIP & publications. #bench-to-bedside

I advise & consult on early biotech projects, therapeutic pipeline projects and platforms as well as developability assessments of lead panels up to Candidate Selection and CLD. Deep expertise in applying Quality by Design, defining Target Product Profiles & implementing robust processes for a variety of different therapeutic modalities. Flexible approach to meet your needs.

Lexington, Massachusetts, Us

I rebuilt a dedicated team of scientists to support ambitious manufacturing CLD projects @ Agenus to RCB. Innovative and disruptive 'Ways of Working' enable on-time delivery of mAb and multi-specific NBE lead candidates in readiness of manufacture. Team efforts are fully aligned to Lead Discovery & Protein Science Departments to maximize on >>Best Science and Speed<<.

Lexington, Massachusetts, Us

I accomplish complex and stretched objectives through a high performing team of dedicated protein biochemists & engineers supporting and driving the entire NBE AGENUS pipeline through to Candidate Selection and INDs. I am modality agnostic in my commitment to fight human disease by strategically employing AGENUS' proprietary therapeutic platforms to select best candidates and outcomes for patients.

Brentford, Middlesex, Gb

Touting for external platform and technology opportunities to supplement GSK's Cell&Gene Therapy ambition. Aligning with Therapy Area Units to define and realise the best synergy between external technologies and value to GSK and future patients.

Brentford, Middlesex, Gb

I project managed GSK's first internal CAR-T (chimeric antigen receptor) C> Platform team establishing internal technical capabilities while simultaneously aligning stakeholder expectations and ways of working across different teams. The project now has been terminated due to strategic considerations, however with processes, protocols and functional assays in place to be used by the next therapeutic CART project @ GSK.

Brentford, Middlesex, Gb

I was accountable for project management & scientific rigour of a biopharm/sustained release feasibility study (‘monthly dosing interval for clinical AlbudAbTM asset’). I conducted the landscape analysis, due diligence & stakeholder management right from inception of the project. The progression of the collaboration was challenged by the termination of the clinical asset (DEC14), which I communicated in a transparent manner to internal & external partners. Following a stringent Target&Product Profile, the evaluation has achieved every success criteria within budget and on time. I was commended by internal & external stakeholders for my scientific lead and communication.

Brentford, Middlesex, Gb

Characterisation of novel NBE formats ('3rd generation') to enable CMC, developability and mechanistic (biological MoA) data package for therapeutic partners and pre-clinical entry. Requires close engagement with various departments from USP/DSP, biology, global safety and IP.

Brentford, Middlesex, Gb

I was the program lead of the 'AlbudAb Platform Technology', a serum half-life extending technology for biologics/NBEs as well as NCEs. Numerous AlbudAb-based therapeutics now have entered pre-clinical/clinical development. I also continue to be group leader for the bio-analytics for the targeted BDU, Cambridge, with ever extending analytical capabilities, focussing on in-solution states, forced degradation and structural information.

Brentford, Middlesex, Gb

Group Leader for the quantitative analysis and characterisation of antibody variable domains (dAbs) as single dAbs and final therapeutic drug candidates using DLS, DSC, AUC, MALLS, BIAcore amongst other routine laboratory techniques.Lead candidate selection based on solution properties and bio-informatics.

Gb

Characterisation of single domain antibodies (dAbs) as a new entity of fully sized IgG molecules as potential drugs. Basic research and publication-focussed with emphasis on phage selections and dAb expression.

Swindon, Gb

Domantis sponsored Post doc with Nobel Price Laureate (2018) Sir Gregory Winter on the biophysical characterisation of single-domain antibodies. This work has been continued and expanded into a full time engagement at Domantis.

Ph.D., Ph.D Course - Biophysics; Cancer Research

Diploma (Masters Degree); Diploma, Molecular Biology/Plant Sciences; Biology

Abitur